[1]肺腺癌患者新鲜细胞学标本EGFR基因突变检测及意义 [2]Epidermal Growth Factor Receptor-Targeted Neoantigen Peptide Vaccination for the Treatment of Non-Small Cell Lung Cancer and Glioblastoma [3]Factors Associating with Bone-Only Metastasis in Chinese Breast Cancer Patients in the Absence of Anti-Human Epidermal Growth Factor Receptor 2-Targeted Therapy [4]Detection of an EML4-ALK fusion mutation secondary to epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy for lung cancer: a case report [5]Evaluating the Efficacy of EGFR-TKIs Combined With Radiotherapy in Advanced Lung Adenocarcinoma Patients With EGFR Mutation: A Retrospective Study [6]伴表皮生长因子受体基因突变的肺腺癌转移至口腔两例 [7]EGFR基因突变阳性肺腺癌脑转移患者治疗后颅内失败的临床研究 [8]Expert consensus on the clinical diagnosis and targeted therapy of HER2 breast cancer (2023 edition) [9]The relationship between EGFR mutation status and clinic-pathologic features in pulmonary adenocarcinoma [10]Icotinib, an EGFR tyrosine kinase inhibitor, as adjuvant therapy for patients with stage IIA-IIIA EGFR-mutant non-small-cell lung adenocarcinoma: a multicenter, open-label, single-arm, phase II study (ICAPE)